Published in Int J Gynecol Cancer on August 03, 2006
The indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells. PLoS One (2011) 1.32
Expression profiles of human interferon-alpha and interferon-lambda subtypes are ligand- and cell-dependent. Immunol Cell Biol (2012) 1.08
Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment. J Immunol (2009) 1.07
Chimeric NKG2D T cells require both T cell- and host-derived cytokine secretion and perforin expression to increase tumor antigen presentation and systemic immunity. J Immunol (2009) 1.00
A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer. Gynecol Oncol (2009) 0.84
The Unique Molecular and Cellular Microenvironment of Ovarian Cancer. Front Oncol (2017) 0.81
Effects of interferons and double-stranded RNA on human prostate cancer cell apoptosis. Oncotarget (2015) 0.78
Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety. Semin Oncol (2014) 0.77
The synergistic interaction between the calcineurin B subunit and IFN-γ enhances macrophage antitumor activity. Cell Death Dis (2015) 0.77
PEGylation improves the pharmacokinetic properties and ability of interferon gamma to inhibit growth of a human tumor xenograft in athymic mice. J Interferon Cytokine Res (2014) 0.75
Interferon signaling in ascites-associated macrophages is linked to a favorable clinical outcome in a subgroup of ovarian carcinoma patients. BMC Genomics (2017) 0.75
Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res (2001) 1.57
First coitus before menarche and risk of sexually transmitted disease. Lancet (1990) 1.55
[Hepatitis B and C: incidence and regional distribution of hospitalizations in Austria]. Wien Klin Wochenschr (2000) 1.40
Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients. Onkologie (2003) 1.38
Interference by toxic metal ions with DNA repair processes and cell cycle control: molecular mechanisms. Environ Health Perspect (2002) 1.37
Leiomyosarcoma of the uterus: a clinicopathologic multicenter study of 71 cases. Gynecol Oncol (1999) 1.34
Prognostic parameters in endometrial stromal sarcoma: a clinicopathologic study in 31 patients. Gynecol Oncol (2001) 1.33
Global sequence diversity of BRCA2: analysis of 71 breast cancer families and 95 control individuals of worldwide populations. Hum Mol Genet (1999) 1.24
Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet Gynecol (1995) 1.17
Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer (2000) 1.17
Interference by toxic metal ions with zinc-dependent proteins involved in maintaining genomic stability. Food Chem Toxicol (2002) 1.03
Consolidation radiotherapy after carboplatin-based chemotherapy in radically operated advanced ovarian cancer. Gynecol Oncol (1999) 1.01
Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study. Ann Oncol (2011) 1.00
Spontaneous vaginal delivery in the birth-chair versus in the conventional dorsal position: a matched controlled comparison. Wien Klin Wochenschr (2001) 0.98
Thrombocytosis as a prognostic factor in endometrial carcinoma. Gynecol Oncol (1998) 0.94
Seroepidemiological and socioeconomic studies of genital chlamydial infection in Ethiopian women. Genitourin Med (1992) 0.93
Vesicocutaneous fistula mimicking an abdominal wall abscess 2 years after radical abdominal hysterectomy. Gynecol Oncol (2003) 0.91
[Wound rupture after Misgav-Ladach cesarean section: a case report]. Gynakol Geburtshilfliche Rundsch (2004) 0.90
Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. Br J Cancer (2011) 0.90
Prognostic relevance of three histological grading methods in breast cancer. Int J Oncol (2001) 0.89
Preoperative thrombocytosis is an independent prognostic factor in stage III and IV endometrial cancer. Anticancer Res (2001) 0.89
Seroepidemiological study of gonorrhoea in Ethiopian women. 2. Socioeconomic picture. Genitourin Med (1991) 0.89
Pretreatment hemoglobin, platelet count, and prognosis in endometrial carcinoma. Int J Gynecol Cancer (2001) 0.87
Significance of pretreatment serum hemoglobin and survival in epithelial ovarian cancer. Oncol Rep (2000) 0.86
Inguinal lymph node metastasis as the only manifestation of lymphatic spread in ovarian cancer: A case report. Gynecol Oncol (1999) 0.86
Phase II study of single-agent pegylated liposomal doxorubicin HCl (PLD) in metastatic breast cancer after first-line treatment failure. Onkologie (2004) 0.86
A randomized phase II study of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer. Ann Oncol (2003) 0.86
Male breast cancer: Austrian experience. World J Surg (1995) 0.85
Long-term control of bone marrow carcinosis and severe thrombocytopenia with standard-dose chemotherapy in a breast cancer patient: a case report. Anticancer Res (2006) 0.85
Vascular damage induced by type 2 diabetes mellitus as a risk factor for benign prostatic hyperplasia. Diabetologia (2005) 0.84
A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML). Leuk Res (2003) 0.84
Primary serous papillary carcinoma of the peritoneum: a report of 18 patients. Eur J Gynaecol Oncol (1997) 0.83
Seroepidemiological studies of Haemophilus ducreyi infection in Ethiopian women. Sex Transm Dis (1995) 0.83
Teenage obstetric and gynaecological problems in an African city. Cent Afr J Med (1994) 0.83
Seroepidemiological study of gonorrhoea in Ethiopian women. 1. Prevalence and clinical significance. Genitourin Med (1991) 0.83
Cord blood oxygen saturation in vigorous infants at birth: what is normal? BJOG (2000) 0.82
The prognostic significance of peritoneal seeding and size of postsurgical residual in patients with stage III epithelial ovarian cancer treated with surgery, chemotherapy, and high-dose radiotherapy. Gynecol Oncol (1999) 0.82
Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer. J Clin Oncol (1999) 0.82
A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer. Br J Cancer (2005) 0.82
Prognostic significance of tumor cell morphometry, histopathology, and clinical parameters in advanced ovarian carcinoma. Int J Gynecol Pathol (1990) 0.82
In vitro chemosensitivity testing in the treatment of ovarian carcinoma. Arch Gynecol Obstet (1989) 0.81
Pelvic lymphadenectomy in the surgical treatment of endometrial cancer. Gynecol Oncol (1993) 0.81
Long-term survival of a patient with fallopian tube cancer presenting with a supraclavicular mass. Anticancer Res (2001) 0.79
Do primiparas aged 40 years or older carry an increased obstetric risk? Prev Med (1999) 0.79
[Importance of the composition of various combination regimens in the chemotherapy of metastatic breast cancer]. Dtsch Med Wochenschr (1987) 0.79
On the relevance of "second-line" cytotoxic chemotherapy in patients with metastatic breast cancer resistant to standard combinations. Wien Klin Wochenschr (1986) 0.79
Characterization of in vitro chemosensitivity of perioperative human ovarian malignancies by adenosine triphosphate chemosensitivity assay. Am J Obstet Gynecol (1991) 0.79
Toxicological potential of 2-alkylcyclobutanones--specific radiolytic products in irradiated fat-containing food--in bacteria and human cell lines. Food Chem Toxicol (2007) 0.78
Very low-dose adjuvant chemotherapy in steroid receptor negative stage I breast cancer patients. Austrian Breast Cancer Study Group. Eur J Cancer (1998) 0.78
Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients. Austrian Breast Cancer Study Group. Eur J Cancer (1999) 0.78
Feasible model for locoregional and systemic longterm administration of drugs and concomitant blood sampling in Sprague-Dawley rats. J Cancer Res Clin Oncol (1987) 0.78
[Imaging of prostate cancer by diagnostic radiology and nuclear medicine]. Aktuelle Urol (2010) 0.78
Adjunctive interferon-alpha-2c in stage IIIB/IV small-cell lung cancer: a phase III trial. Eur Respir J (1997) 0.77
Prevalence of pre-malignant and malignant lesions in prophylactic mastectomy specimens of BRCA1 mutation carriers: comparison with a control group. J Cancer Res Clin Oncol (2008) 0.77
Sigmoid model versus median-effect analysis for obtaining dose-response curves for in vitro chemosensitivity testing. Int J Clin Pharmacol Ther (1999) 0.77
Is cervical cancer in Ethiopian women the result of a sexually transmitted disease? Int Surg (1993) 0.77
[Therapy studies of the Austrian Breast Cancer Group (ABC)]. Zentralbl Chir (1998) 0.77
Chemical enhancement of cisplatin cytotoxicity in a human ovarian and cervical cancer cell line. Gynecol Oncol (1990) 0.77
Possible influence of granulocyte colony-stimulating factor and recombinant human erythropoietin on human chorionic gonadotropin secretion during chemotherapy for choriocarcinoma. Gynecol Oncol (2001) 0.76
Consolidation radiotherapy following carboplatin-based chemotherapy in radically operated advanced ovarian cancer. A pilot study. Am J Clin Oncol (1991) 0.76
Therapeutic ratio of mono or combination bacterial lipopolysaccharide therapy in methylnitrosourea-induced rat mammary carcinoma. J Cancer Res Clin Oncol (1987) 0.76
Treatment of herpes zoster. Recombinant alpha interferon versus acyclovir. Int J Dermatol (1988) 0.76
Stage IV ovarian cancer: prognostic factors and survival beyond 5 years. Anticancer Res (2002) 0.75
Prognostic parameters in carcinosarcomas of the uterus: a clinico-pathologic study. Anticancer Res (2001) 0.75
Influence of perinatal nicotine administration on transplacental carcinogenesis in Sprague Dawley rats by N-methylnitrosourea. Br J Cancer (1987) 0.75
Dose related effectiveness of alpha interferon in chronic myelogenous leukemia. Blut (1987) 0.75
Re: intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol (2006) 0.75
Re: "Selenium as an element in the treatment of ovarian cancer in women receiving chemotherapy". Gynecol Oncol (2005) 0.75
Metabolism of debrisoquine and susceptibility to breast cancer. Breast Cancer Res Treat (1991) 0.75
CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trial. J Clin Oncol (1996) 0.75
[Chemotherapy and prognostic significance of the size of the remaining tumor in ovarian cancer]. Gynakol Rundsch (1989) 0.75
Treatment of chemically induced autochthonous rat mammary and colorectal carcinomas with interleukin-2. Cancer Immunol Immunother (1991) 0.75
Cytostatic activity of an estradiol-linked nitrosourea in MXT mammary carcinoma and L 5222 leukemia. Arzneimittelforschung (1989) 0.75
[The obstetric risk in adolescent primiparous females]. Geburtshilfe Frauenheilkd (1989) 0.75
[Perinatal stress factors and sudden infant death (SIDS)]. Gynakol Rundsch (1988) 0.75
[Pretherapeutic scalenus biopsy in ovarian cancer]. Gynakol Rundsch (1991) 0.75
[Current status of diagnosis and therapy of trophoblast tumors]. Gynakol Rundsch (1990) 0.75
[Aggressive follow-up of a young patient with small cell cervix cancer]. Gynakol Geburtshilfliche Rundsch (1993) 0.75
[Scalenus biopsy in diagnosis of ovarian and uterine cancers]. HNO (1990) 0.75
Interferon-alpha for the treatment of elderly patients with chronic myeloid leukaemia. Leuk Res (1998) 0.75
[Lymph cysts following radical operations of cervix and ovarian cancer]. Gynakol Rundsch (1990) 0.75
[Lymph node status in corpus and cervix cancer]. Gynakol Rundsch (1991) 0.75
Toxicity and preliminary results with a new eight-drug regimen (CEOP-IMVP-DEXA) in the treatment of aggressive lymphomas. Hematol Oncol (1992) 0.75
Interferon-alpha-2C and LD ara-C for the treatment of patients with CML: results of the Austrian multi-center phase II study. Leuk Res (1997) 0.75
Efficacy of adjuvant carboplatin-epirubicin chemotherapy in advanced ovarian cancer after radical surgery. Oncology (1989) 0.75
Pirarubicin (4'-o-tetrahydropyranil-adriamycin) for treatment of advanced breast cancer. A Clinical Phase II study. Invest New Drugs (1990) 0.75
Parity as an independent prognostic factor in malignant mixed mesodermal tumors of the endometrium. Gynecol Oncol (1997) 0.75
Pelvic and para-aortic lymphadenectomy in cervical cancer. Baillieres Clin Obstet Gynaecol (1988) 0.75
Prognostic implications of residual tumour volume in stage III ovarian cancer patients undergoing adjuvant cytotoxic chemotherapy. Baillieres Clin Obstet Gynaecol (1989) 0.75
[Hydatidiform mole, trophoblastic tumor/choriocarcinoma]. Gynakol Geburtshilfliche Rundsch (1992) 0.75
Perioperative antibiotic prophylaxis in patients undergoing radical surgery for gynecologic cancer: single dose versus multiple dose administration. Eur J Gynaecol Oncol (1993) 0.75
[Therapy of uterine cancer: a review]. Gynakol Rundsch (1988) 0.75
[Change in obstetrical risk in adolescent primiparous patients--a comparative study]. Gynakol Rundsch (1989) 0.75
[Immunity of habitual abortion. Principles and current status of research]. Gynakol Rundsch (1988) 0.75
Combination treatment based on metabolic effects of dinaline. J Cancer Res Clin Oncol (1995) 0.75
[Diagnostic value of combined vaginal ultrasound and hysteroscopy in peri- and postmenopausal bleeding]. Gynakol Geburtshilfliche Rundsch (1996) 0.75
Macroprolactinomas and functionless pituitary tumours. Immunostaining and effect of dopamine agonist therapy. Acta Endocrinol (Copenh) (1987) 0.75
[The value of preventive ovariectomy at the time of hysterectomy for prevention of ovarian cancer]. Gynakol Rundsch (1991) 0.75
The value of morphometry to predict chemotherapy response in advanced ovarian cancer. Pathol Res Pract (1989) 0.75